Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021BOSTON, June 03, 2020 (GLOBE NEWSWIRE) […]